A new drug with a new target
Microarrays yield a 115-gene signature
CDC Released Misleading Obesity Stats
Matching binding compounds to targets
How it works and for who?
Shakedown at the FDA Under intense public scrutiny following the withdrawal of Vioxx from the market based on evidence of increased heart attack and stroke, the FDA is now defending its role as an independent and unbiased protector of the public against dangerous drugs.
Identifies function in insulin secretion
Integrated gene expression and genotyping technologies
A massive library and a new robotic HT screening platform The National Institutes of Health
Recaping the Scientific American Targeted Medicine conference
By Elizabeth Tolchin
Ni Sepharose 6 Fast Flow medium purifies His-tagged proteins and provides reliable and cost-effective scale-up. Large 90 μm bead size minimizes problems associated with back-pressure at high flow rates, and enables large volumes to be purified.
X-tremeGENE siRNA transfection reagent allows knockdown experiments with siRNA and co-transfection experiments using siRNA and DNA. The reagent requires no media changes and demonstrates minimal cytotoxicity. It offers broad effectiveness on various cells types and provides effective gene knockdown.
COX-1 Targeted Mutation Mice reveal no physical differences compared to wild-type mice. Upon gross and microscopic examination, organ systems, including the gastrointestinal, respiratory and reproductive tract appear normal and healthy.